Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau
Identifieur interne : 000B79 ( Main/Corpus ); précédent : 000B78; suivant : 000B80Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau
Auteurs : Jean-Marc Taymans ; Mark R. CooksonSource :
- BioEssays [ 0265-9247 ] ; 2010-03.
English descriptors
- KwdEn :
Abstract
Parkinson's disease (PD) is generally sporadic but a number of genetic diseases have parkinsonism as a clinical feature. Two dominant genes, α‐synuclein (SNCA) and leucine‐rich repeat kinase 2 (LRRK2), are important for understanding inherited and sporadic PD. SNCA is a major component of pathologic inclusions termed Lewy bodies found in PD. LRRK2 is found in a significant proportion of PD cases. These two proteins may be linked as most LRRK2 PD cases have SNCA‐positive Lewy bodies. Mutations in both proteins are associated with toxic effects in model systems although mechanisms are unclear. LRRK2 is an intracellular signaling protein possessing both GTPase and kinase activities that may contribute to pathogenicity. A third protein, tau, is implicated as a risk factor for PD. We discuss the potential relationship between these genes and suggest a model for PD pathogenesis where LRRK2 is upstream of pathogenic effects through SNCA, tau, or both proteins.
Url:
DOI: 10.1002/bies.200900163
Links to Exploration step
ISTEX:BAD8011D8F2673D5ABA6187FCDF1135776A1DE8ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau</title><author><name sortKey="Taymans, Jean Arc" sort="Taymans, Jean Arc" uniqKey="Taymans J" first="Jean-Marc" last="Taymans">Jean-Marc Taymans</name><affiliation><mods:affiliation>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, NIA, National Institutes of Health, Bethesda, MD, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Laboratory for Neurobiology and Gene Therapy, Division of Molecular Medicine, Department of Molecular and Cellular Medicine, Katholieke Universiteit Leuven, Leuven, Belgium</mods:affiliation></affiliation></author><author><name sortKey="Cookson, Mark R" sort="Cookson, Mark R" uniqKey="Cookson M" first="Mark R." last="Cookson">Mark R. Cookson</name><affiliation><mods:affiliation>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, NIA, National Institutes of Health, Bethesda, MD, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BAD8011D8F2673D5ABA6187FCDF1135776A1DE8E</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/bies.200900163</idno><idno type="url">https://api.istex.fr/document/BAD8011D8F2673D5ABA6187FCDF1135776A1DE8E/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000B79</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau</title><author><name sortKey="Taymans, Jean Arc" sort="Taymans, Jean Arc" uniqKey="Taymans J" first="Jean-Marc" last="Taymans">Jean-Marc Taymans</name><affiliation><mods:affiliation>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, NIA, National Institutes of Health, Bethesda, MD, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Laboratory for Neurobiology and Gene Therapy, Division of Molecular Medicine, Department of Molecular and Cellular Medicine, Katholieke Universiteit Leuven, Leuven, Belgium</mods:affiliation></affiliation></author><author><name sortKey="Cookson, Mark R" sort="Cookson, Mark R" uniqKey="Cookson M" first="Mark R." last="Cookson">Mark R. Cookson</name><affiliation><mods:affiliation>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, NIA, National Institutes of Health, Bethesda, MD, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">BioEssays</title><title level="j" type="abbrev">Bioessays</title><idno type="ISSN">0265-9247</idno><idno type="eISSN">1521-1878</idno><imprint><publisher>WILEY‐VCH Verlag</publisher><pubPlace>Weinheim</pubPlace><date type="published" when="2010-03">2010-03</date><biblScope unit="volume">32</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="227">227</biblScope><biblScope unit="page" to="235">235</biblScope></imprint><idno type="ISSN">0265-9247</idno></series><idno type="istex">BAD8011D8F2673D5ABA6187FCDF1135776A1DE8E</idno><idno type="DOI">10.1002/bies.200900163</idno><idno type="ArticleID">BIES200900163</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0265-9247</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>genetics</term><term>kinases</term><term>microtubule</term><term>neurodegeneration</term><term>synapse</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is generally sporadic but a number of genetic diseases have parkinsonism as a clinical feature. Two dominant genes, α‐synuclein (SNCA) and leucine‐rich repeat kinase 2 (LRRK2), are important for understanding inherited and sporadic PD. SNCA is a major component of pathologic inclusions termed Lewy bodies found in PD. LRRK2 is found in a significant proportion of PD cases. These two proteins may be linked as most LRRK2 PD cases have SNCA‐positive Lewy bodies. Mutations in both proteins are associated with toxic effects in model systems although mechanisms are unclear. LRRK2 is an intracellular signaling protein possessing both GTPase and kinase activities that may contribute to pathogenicity. A third protein, tau, is implicated as a risk factor for PD. We discuss the potential relationship between these genes and suggest a model for PD pathogenesis where LRRK2 is upstream of pathogenic effects through SNCA, tau, or both proteins.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Jean‐Marc Taymans</name><affiliations><json:string>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, NIA, National Institutes of Health, Bethesda, MD, USA</json:string><json:string>Laboratory for Neurobiology and Gene Therapy, Division of Molecular Medicine, Department of Molecular and Cellular Medicine, Katholieke Universiteit Leuven, Leuven, Belgium</json:string></affiliations></json:item><json:item><name>Mark R. Cookson</name><affiliations><json:string>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, NIA, National Institutes of Health, Bethesda, MD, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>genetics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>kinases</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>microtubule</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neurodegeneration</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>synapse</value></json:item></subject><articleId><json:string>BIES200900163</json:string></articleId><language><json:string>eng</json:string></language><abstract>Parkinson's disease (PD) is generally sporadic but a number of genetic diseases have parkinsonism as a clinical feature. Two dominant genes, α‐synuclein (SNCA) and leucine‐rich repeat kinase 2 (LRRK2), are important for understanding inherited and sporadic PD. SNCA is a major component of pathologic inclusions termed Lewy bodies found in PD. LRRK2 is found in a significant proportion of PD cases. These two proteins may be linked as most LRRK2 PD cases have SNCA‐positive Lewy bodies. Mutations in both proteins are associated with toxic effects in model systems although mechanisms are unclear. LRRK2 is an intracellular signaling protein possessing both GTPase and kinase activities that may contribute to pathogenicity. A third protein, tau, is implicated as a risk factor for PD. We discuss the potential relationship between these genes and suggest a model for PD pathogenesis where LRRK2 is upstream of pathogenic effects through SNCA, tau, or both proteins.</abstract><qualityIndicators><score>6.788</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>6</keywordCount><abstractCharCount>967</abstractCharCount><pdfWordCount>7336</pdfWordCount><pdfCharCount>45847</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>149</abstractWordCount></qualityIndicators><title>Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau</title><genre><json:string>article</json:string></genre><host><volume>32</volume><publisherId><json:string>BIES</json:string></publisherId><pages><total>9</total><last>235</last><first>227</first></pages><issn><json:string>0265-9247</json:string></issn><issue>3</issue><subject><json:item><value>Problems and paradigms</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1521-1878</json:string></eissn><title>BioEssays</title><doi><json:string>10.1002/(ISSN)1521-1878</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/bies.200900163</json:string></doi><id>BAD8011D8F2673D5ABA6187FCDF1135776A1DE8E</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/BAD8011D8F2673D5ABA6187FCDF1135776A1DE8E/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/BAD8011D8F2673D5ABA6187FCDF1135776A1DE8E/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/BAD8011D8F2673D5ABA6187FCDF1135776A1DE8E/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>WILEY‐VCH Verlag</publisher><pubPlace>Weinheim</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau</title><author><persName><forename type="first">Jean‐Marc</forename><surname>Taymans</surname></persName><affiliation>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, NIA, National Institutes of Health, Bethesda, MD, USA</affiliation><affiliation>Laboratory for Neurobiology and Gene Therapy, Division of Molecular Medicine, Department of Molecular and Cellular Medicine, Katholieke Universiteit Leuven, Leuven, Belgium</affiliation></author><author><persName><forename type="first">Mark R.</forename><surname>Cookson</surname></persName><note type="correspondence"><p>Correspondence: Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, National Institute on Aging, 35 Convent Drive, Bethesda, MD 20892‐3707, USA.</p></note><affiliation>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, NIA, National Institutes of Health, Bethesda, MD, USA</affiliation></author></analytic><monogr><title level="j">BioEssays</title><title level="j" type="abbrev">Bioessays</title><idno type="pISSN">0265-9247</idno><idno type="eISSN">1521-1878</idno><idno type="DOI">10.1002/(ISSN)1521-1878</idno><imprint><publisher>WILEY‐VCH Verlag</publisher><pubPlace>Weinheim</pubPlace><date type="published" when="2010-03"></date><biblScope unit="volume">32</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="227">227</biblScope><biblScope unit="page" to="235">235</biblScope></imprint></monogr><idno type="istex">BAD8011D8F2673D5ABA6187FCDF1135776A1DE8E</idno><idno type="DOI">10.1002/bies.200900163</idno><idno type="ArticleID">BIES200900163</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Parkinson's disease (PD) is generally sporadic but a number of genetic diseases have parkinsonism as a clinical feature. Two dominant genes, α‐synuclein (SNCA) and leucine‐rich repeat kinase 2 (LRRK2), are important for understanding inherited and sporadic PD. SNCA is a major component of pathologic inclusions termed Lewy bodies found in PD. LRRK2 is found in a significant proportion of PD cases. These two proteins may be linked as most LRRK2 PD cases have SNCA‐positive Lewy bodies. Mutations in both proteins are associated with toxic effects in model systems although mechanisms are unclear. LRRK2 is an intracellular signaling protein possessing both GTPase and kinase activities that may contribute to pathogenicity. A third protein, tau, is implicated as a risk factor for PD. We discuss the potential relationship between these genes and suggest a model for PD pathogenesis where LRRK2 is upstream of pathogenic effects through SNCA, tau, or both proteins.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>genetics</term></item><item><term>kinases</term></item><item><term>microtubule</term></item><item><term>neurodegeneration</term></item><item><term>Parkinson's disease</term></item><item><term>synapse</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Problems and paradigms</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-03">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/BAD8011D8F2673D5ABA6187FCDF1135776A1DE8E/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>WILEY‐VCH Verlag</publisherName><publisherLoc>Weinheim</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1521-1878</doi><issn type="print">0265-9247</issn><issn type="electronic">1521-1878</issn><idGroup><id type="product" value="BIES"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="BIOESSAYS">BioEssays</title><title type="short">Bioessays</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/bies.v32:3</doi><numberingGroup><numbering type="journalVolume" number="32">32</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="2010-03">March 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="9" status="forIssue"><doi origin="wiley" registered="yes">10.1002/bies.200900163</doi><idGroup><id type="unit" value="BIES200900163"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="articleCategory">Problems and paradigms</title><title type="tocHeading1">Problems and paradigms</title></titleGroup><copyright ownership="publisher">Copyright © 2010 Wiley Periodicals, Inc.</copyright><eventGroup><event type="firstOnline" date="2010-02-01"></event><event type="publishedOnlineFinalForm" date="2010-02-16"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.16 mode:FullText" date="2010-08-30"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-22"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-15"></event></eventGroup><numberingGroup><numbering type="pageFirst">227</numbering><numbering type="pageLast">235</numbering></numberingGroup><correspondenceTo>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, National Institute on Aging, 35 Convent Drive, Bethesda, MD 20892‐3707, USA.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:BIES.BIES200900163.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="117"></count><count type="wordTotal" number="7472"></count></countGroup><titleGroup><title type="main" xml:lang="en">Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau</title><title type="short" xml:lang="en">Problems and paradigms</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Jean‐Marc</givenNames><familyName>Taymans</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Mark R.</givenNames><familyName>Cookson</familyName></personName><contactDetails><email>cookson@mail.nih.gov</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, NIA, National Institutes of Health, Bethesda, MD, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="BE" type="organization"><unparsedAffiliation>Laboratory for Neurobiology and Gene Therapy, Division of Molecular Medicine, Department of Molecular and Cellular Medicine, Katholieke Universiteit Leuven, Leuven, Belgium</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">genetics</keyword><keyword xml:id="kwd2">kinases</keyword><keyword xml:id="kwd3">microtubule</keyword><keyword xml:id="kwd4">neurodegeneration</keyword><keyword xml:id="kwd5">Parkinson's disease</keyword><keyword xml:id="kwd6">synapse</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Parkinson's disease (PD) is generally sporadic but a number of genetic diseases have parkinsonism as a clinical feature. Two dominant genes, α‐synuclein (<i>SNCA</i>) and leucine‐rich repeat kinase 2 (<i>LRRK2</i>), are important for understanding inherited and sporadic PD. <i>SNCA</i> is a major component of pathologic inclusions termed Lewy bodies found in PD. LRRK2 is found in a significant proportion of PD cases. These two proteins may be linked as most LRRK2 PD cases have <i>SNCA</i>‐positive Lewy bodies. Mutations in both proteins are associated with toxic effects in model systems although mechanisms are unclear. LRRK2 is an intracellular signaling protein possessing both GTPase and kinase activities that may contribute to pathogenicity. A third protein, tau, is implicated as a risk factor for PD. We discuss the potential relationship between these genes and suggest a model for PD pathogenesis where LRRK2 is upstream of pathogenic effects through <i>SNCA</i>, tau, or both proteins.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Problems and paradigms</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau</title></titleInfo><name type="personal"><namePart type="given">Jean‐Marc</namePart><namePart type="family">Taymans</namePart><affiliation>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, NIA, National Institutes of Health, Bethesda, MD, USA</affiliation><affiliation>Laboratory for Neurobiology and Gene Therapy, Division of Molecular Medicine, Department of Molecular and Cellular Medicine, Katholieke Universiteit Leuven, Leuven, Belgium</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mark R.</namePart><namePart type="family">Cookson</namePart><affiliation>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, NIA, National Institutes of Health, Bethesda, MD, USA</affiliation><description>Correspondence: Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, National Institute on Aging, 35 Convent Drive, Bethesda, MD 20892‐3707, USA.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>WILEY‐VCH Verlag</publisher><place><placeTerm type="text">Weinheim</placeTerm></place><dateIssued encoding="w3cdtf">2010-03</dateIssued><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="references">117</extent><extent unit="words">7472</extent></physicalDescription><abstract lang="en">Parkinson's disease (PD) is generally sporadic but a number of genetic diseases have parkinsonism as a clinical feature. Two dominant genes, α‐synuclein (SNCA) and leucine‐rich repeat kinase 2 (LRRK2), are important for understanding inherited and sporadic PD. SNCA is a major component of pathologic inclusions termed Lewy bodies found in PD. LRRK2 is found in a significant proportion of PD cases. These two proteins may be linked as most LRRK2 PD cases have SNCA‐positive Lewy bodies. Mutations in both proteins are associated with toxic effects in model systems although mechanisms are unclear. LRRK2 is an intracellular signaling protein possessing both GTPase and kinase activities that may contribute to pathogenicity. A third protein, tau, is implicated as a risk factor for PD. We discuss the potential relationship between these genes and suggest a model for PD pathogenesis where LRRK2 is upstream of pathogenic effects through SNCA, tau, or both proteins.</abstract><subject lang="en"><genre>Keywords</genre><topic>genetics</topic><topic>kinases</topic><topic>microtubule</topic><topic>neurodegeneration</topic><topic>Parkinson's disease</topic><topic>synapse</topic></subject><relatedItem type="host"><titleInfo><title>BioEssays</title></titleInfo><titleInfo type="abbreviated"><title>Bioessays</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Problems and paradigms</topic></subject><identifier type="ISSN">0265-9247</identifier><identifier type="eISSN">1521-1878</identifier><identifier type="DOI">10.1002/(ISSN)1521-1878</identifier><identifier type="PublisherID">BIES</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>227</start><end>235</end><total>9</total></extent></part></relatedItem><identifier type="istex">BAD8011D8F2673D5ABA6187FCDF1135776A1DE8E</identifier><identifier type="DOI">10.1002/bies.200900163</identifier><identifier type="ArticleID">BIES200900163</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Wiley Periodicals, Inc.</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>WILEY‐VCH Verlag</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B79 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000B79 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:BAD8011D8F2673D5ABA6187FCDF1135776A1DE8E
|texte= Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau
}}
| This area was generated with Dilib version V0.6.23. |  |